Yes, but P2b didn’t fail and now they have nearly
finished a number of P3 trials with likely DMOAD
action. No good hiding our heads in the sand.
As I intimated earlier, if trial results are good, lets
hope FDA are as pedantic with Bio Splice as
they have been with PAR.
Lorecivivint, page-11
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
-0.010(3.45%) |
Mkt cap ! $97.94M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 28.0¢ | $40.10K | 140.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 135929 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 20969 | 2 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |